Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 2/20 | 0.58 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.45 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.43 |
| ▸ | KCNN1 | Q92952 | 1/20 | 0.43 |
| ▸ | KCNN2 | Q9H2S1 | 1/20 | 0.43 |
| ▸ | KCNN3 | Q9UGI6 | 1/20 | 0.43 |
| ▸ | PRCP | P42785 | 1/20 | 0.41 |
| ▸ | RHEB | Q15382 | 2/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.40 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.40 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.40 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.40 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.40 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.40 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7214221 | 0.78 | RIPK1 (0.46) | RIPK1KCNN1KCNN2KCNN3RHEB | |
| SCHEMBL577711 | 0.75 | RIPK1 (0.44) | RIPK1CACNA1GCACNA1HGAAHTT | |
| SCHEMBL577712 | 0.75 | RIPK1 (0.44) | RIPK1CACNA1GCACNA1HGAAHTT | |
| SCHEMBL7208898 | 0.74 | PIM1 (0.45) | RIPK1KCNN1KCNN2KCNN3RHEB | |
| SCHEMBL27203390 | 0.73 | CACNA1G (0.49) | RIPK1CACNA1GCACNA1HGAAHTT | |
| SCHEMBL29770413 | 0.73 | CACNA1G (0.49) | RIPK1CACNA1GCACNA1HGAAHTT | |
| SCHEMBL28406604 | 0.72 | HDAC6 (0.57) | RIPK1KCNN3 | |
| SCHEMBL13804780 | 0.72 | CACNA1H (0.51) | CACNA1GCACNA1HGAAHTTRHEB | |
| SCHEMBL7215070 | 0.71 | GAA (0.49) | CACNA1GCACNA1HGAAHTTRHEB | |
| SCHEMBL439758 | 0.71 | GAA (0.49) | CACNA1GCACNA1HGAAHTTRHEB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010003744-A1 | Therapeutic compounds | CHAMBERLAIN STANLEY DAWES (US) | 2001-06-14 | — | — | US | claimed |
| EP-0769017-A1 | THERAPEUTIC COMPOUNDS | THE WELLCOME FOUNDATION LIMITED (GB) | 1997-04-23 | — | — | EP | claimed |
| WO-1996001833-A1 | THERAPEUTIC COMPOUNDS | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-01-25 | — | — | WO | claimed |
| US-6617315-B1 | Sugar-substituted benzimidazole derivatives are used for the treatment or prophylaxis of restenosis, particularly following angioplasty | CHAMBERLAIN STANLEY DAWES (US) | 2003-09-09 | — | — | US | disclosed |
| US-6413938-B1 | HERPES VIRUS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2002-07-02 | — | — | US | disclosed |
| US-6307043-B1 | FOR TREATMENT OR PROPHYLAXIS OF HERPES VIRAL INFECTIONS | GLAXO WELLCOME INC. | 2001-10-23 | — | — | US | disclosed |
| US-20010003744-A1 | Therapeutic compounds | CHAMBERLAIN STANLEY DAWES (US) | 2001-06-14 | — | — | US | disclosed |
| US-6204249-B1 | L-benzimidazole nucleosides | GLAXO WELLCOME INC. | 2001-03-20 | — | — | US | disclosed |
| US-6077832-A | FOR THERAPY AND PROPHYLAXIS OF HERPES VIRUS INFECTION | GLAXO WELLCOME INC. (US) | 2000-06-20 | — | — | US | disclosed |
| EP-0769017-B1 | THERAPEUTIC COMPOUNDS | WELLCOME FOUND (GB) | 2000-05-24 | — | — | EP | disclosed |
| EP-0970100-A1 | BENZIMIDAZOLE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2000-01-12 | — | — | EP | disclosed |
| US-5998605-A | Antiviral benzimidazole nucleoside analogues and method for their preparation | GLAXO WELLCOME INC. (US) | 1999-12-07 | — | — | US | disclosed |
| WO-1998035977-A1 | BENZIMIDAZOLE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1998-08-20 | — | — | WO | disclosed |
| EP-0769017-A1 | THERAPEUTIC COMPOUNDS | THE WELLCOME FOUNDATION LIMITED (GB) | 1997-04-23 | — | — | EP | disclosed |
| WO-1996001833-A1 | THERAPEUTIC COMPOUNDS | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010003744-A1 | Therapeutic compounds | ZC3HAV1, HAVCR2, EIF2AK2 | RIPK1 3004/4885CACNA1G 3294/4885CACNA1H 3543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.